Replaces Prod. #: ALX-350-251
Potent and selective inhibitor of CDKs. Selective for CDK1/cyclin B kinase (IC50=450nM) [2], CDK2 (IC50=700nM) [4] and CDK5/p35 (IC50=160nM) [4,5]. More potent than olomoucine (Prod. No. BML-CC200). Inhibits M phase promoting factor (MPF) kinase activity. Has effects on calcium channel gating.
Product Details
Alternative Name: | 6-Benzylamino-2-(R)-[(1-ethyl)-2-hydroxyethylamino]-9-isopropylpurine, 2(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, Seliciclib |
|
Formula: | C19H26N6O |
|
MW: | 354.4 |
|
CAS: | 186692-46-6 |
|
Purity: | ≥95% (HPLC, TLC) |
|
Appearance: | White to off-white solid. |
|
Solubility: | Soluble in DMSO. |
|
Shipping: | Shipped on Dry Ice |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Roscovitine differentially affects CaV2 and Kv channels by binding to the open state: Z. Buraei, et al.; Neuropharmacology
52, 883 (2007),
Abstract;
The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction: S. Cho & S.D. Meriney; Eur. J. Neurosci.
23, 3200 (2006),
Abstract;
Roscovitine targets, protein kinases and pyridoxal kinase: S. Bach, et al.; J. Biol. Chem.
280, 31208 (2005),
Abstract;
Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons: E.A. Monaco, 3rd, et al.; Biochem. Pharmacol.
67, 1947 (2004),
Abstract;
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials: L. Meijer & E. Raymond; Acc. Chem. Res.
36, 417 (2003), (Review),
Abstract;
The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J.
371, 199 (2003),
Abstract;
Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia: N. Sankrithi & A. Eskin; J. Neurochem.
72, 605 (1999),
Abstract;
Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin- dependent kinases: L.M. Schang, et al.; J. Virol.
73, 2161 (1999),
Abstract;
Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine: J.S. Yakisich, et al.; BBRC
243, 674 (1998),
Abstract;
The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity: F. Alessi, et al.; Exp. Cell Res.
245, 8 (1998),
Abstract;
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5: L. Meijer, et al.; Eur. J. Biochem.
243, 527 (1997),
Abstract;
Chemical inhibitors of cyclin-dependent kinases: L. Meijer and S.H. Kim; Meth. Enzymol.
283, 113 (1997),
Abstract;
Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds: L. Havlicek, et al.; J. Med. Chem.
40, 408 (1997),
Abstract;
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist: J.W. Pippin, et al.; J. Clin. Invest.
100, 2512 (1997),
Abstract;
Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine: W.F. De Azvedo, et al.; Eur. J. Biochem.
243, 518 (1997),
Abstract;
Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis: B. Rudolph, et al.; EMBO J.
15, 3065 (1996),
Abstract;